Wakefield Asset Management LLLP Buys Shares of 13,933 LeMaitre Vascular, Inc. $LMAT

Wakefield Asset Management LLLP bought a new stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 13,933 shares of the medical instruments supplier’s stock, valued at approximately $1,130,000.

Several other hedge funds have also recently made changes to their positions in LMAT. Cornerstone Planning Group LLC raised its stake in shares of LeMaitre Vascular by 534.0% in the third quarter. Cornerstone Planning Group LLC now owns 336 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 283 shares during the period. MAI Capital Management bought a new stake in shares of LeMaitre Vascular during the 3rd quarter valued at $38,000. First Horizon Corp bought a new stake in shares of LeMaitre Vascular during the 3rd quarter valued at $39,000. Geneos Wealth Management Inc. raised its stake in shares of LeMaitre Vascular by 250.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 398 shares during the period. Finally, EverSource Wealth Advisors LLC bought a new stake in shares of LeMaitre Vascular during the 2nd quarter valued at $47,000. 84.64% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on LMAT. Freedom Capital upgraded LeMaitre Vascular to a “hold” rating in a research note on Tuesday, March 31st. Weiss Ratings lowered LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a research note on Wednesday, May 6th. Roth Mkm reiterated a “buy” rating and set a $117.00 price objective (up from $108.00) on shares of LeMaitre Vascular in a research note on Thursday, February 26th. Barrington Research boosted their price objective on LeMaitre Vascular from $105.00 to $120.00 and gave the company an “outperform” rating in a research note on Wednesday, May 6th. Finally, Wall Street Zen upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $112.60.

LeMaitre Vascular Price Performance

Shares of NASDAQ LMAT opened at $97.31 on Friday. The firm has a market capitalization of $2.22 billion, a P/E ratio of 35.91, a P/E/G ratio of 2.76 and a beta of 0.60. The company has a quick ratio of 12.20, a current ratio of 14.32 and a debt-to-equity ratio of 0.42. The stock’s 50-day simple moving average is $109.34 and its two-hundred day simple moving average is $94.91. LeMaitre Vascular, Inc. has a twelve month low of $78.35 and a twelve month high of $118.01.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share for the quarter, topping analysts’ consensus estimates of $0.66 by $0.02. The business had revenue of $66.55 million for the quarter, compared to analyst estimates of $66.67 million. LeMaitre Vascular had a return on equity of 15.36% and a net margin of 24.35%.The company’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same period in the prior year, the company earned $0.48 EPS. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. As a group, equities analysts anticipate that LeMaitre Vascular, Inc. will post 3 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 4th. Shareholders of record on Thursday, May 21st will be paid a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date is Thursday, May 21st. LeMaitre Vascular’s dividend payout ratio is currently 36.90%.

Insiders Place Their Bets

In other LeMaitre Vascular news, Director David B. Roberts sold 8,464 shares of the company’s stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $106.80, for a total value of $903,955.20. Following the transaction, the director directly owned 17,979 shares in the company, valued at $1,920,157.20. This represents a 32.01% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Bridget A. Ross sold 5,044 shares of the company’s stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $111.10, for a total value of $560,388.40. Following the completion of the transaction, the director owned 3,942 shares in the company, valued at $437,956.20. This represents a 56.13% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 269,891 shares of company stock valued at $28,969,086 over the last 90 days. 7.40% of the stock is owned by insiders.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.